311 related articles for article (PubMed ID: 32642408)
1. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
Lu Z; Shi X; Gong F; Li S; Wang Y; Ren Y; Zhang M; Yu B; Li Y; Zhao W; Zhang J; Hou G
Acta Pharm Sin B; 2020 Jun; 10(6):1004-1019. PubMed ID: 32642408
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
3. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
6. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
[TBL] [Abstract][Full Text] [Related]
7. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
[TBL] [Abstract][Full Text] [Related]
8. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor-induced Akt phosphorylation requires mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation depends on mTOR/Raptor and phospholipase D.
Razmara M; Heldin CH; Lennartsson J
Cell Commun Signal; 2013 Jan; 11(1):3. PubMed ID: 23311350
[TBL] [Abstract][Full Text] [Related]
10. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
11. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
12. Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.
Bian YH; Xu J; Zhao WY; Zhang ZZ; Tu L; Cao H; Zhang ZG
Am J Transl Res; 2017; 9(9):4317-4330. PubMed ID: 28979705
[TBL] [Abstract][Full Text] [Related]
13. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
[TBL] [Abstract][Full Text] [Related]
14. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
15. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
16. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
17. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
[TBL] [Abstract][Full Text] [Related]
18. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
19. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
[TBL] [Abstract][Full Text] [Related]
20. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
